Tag: prescription

Scaling Self-Care Can Be a Game-Changer in Global Fight Against Non-Communicable Diseases

Ahead of the upcoming UN General Assembly to set a new vision for non-communicable diseases, the Global Self-Care Federation is calling for self-care strategies...

British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)

TORONTO, July 23, 2025 /CNW/ - Elvium Life Sciences is pleased to announce the addition of FOQUEST® (methylphenidate hydrochloride controlled release capsules) to the British...

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Doceree launches co-pay.com, an initiative to build the largest database of co-pay and affordability programs

SHORT HILLS, N.J. , July 22, 2025 /PRNewswire/ -- Doceree, the world's first global network for programmatic HCP engagement, has announced the launch of co-pay.com—the...

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil®...

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil®...

Health In Tech Announces Second Quarter 2025 Financial Results

Revenues of $9.3 million, up 86% YoY; The first-half year revenues of $17.3 million, 89% of full year 2024.Adjusted EBITDA of $1.6 million, up...

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra^® for men - in a proprietary topical formulation demonstrated to work where women need it most

Natural Appetite Suppressant: Why More Are Choosing PhenQ Over Weight Loss Injections for Safer Weight Management Results in 2025

New York City, NY, July 21, 2025 (GLOBE NEWSWIRE) -- PhenQ is leading the 2025 weight loss revolution with a science-backed natural appetite suppressant—no needles, no harsh side effects, just sustainable, healthy weight control

MY DR NOW Adds Seventh Clinic in Mesa with Same-Day Healthcare

MESA, Ariz., July 21, 2025 /PRNewswire/ -- MY DR NOW, Arizona's largest independently owned primary care provider with 60 locations across the state, is...

The Wholesome Company Launches Rē•prev, a Calming Drink Mix for Anxiousness Support

Grapevine, TX, July 21, 2025 (GLOBE NEWSWIRE) -- The Wholesome Company, a wellness brand focused on holistic and evidence-aligned support for mental well-being, is pleased to announce the launch of Rē•prev, a breakthrough nutritional supplement formulated to help individuals reduce anxiousness, manage stress, and improve sleep quality. Designed for rapid absorption and daily use, Rē•prev combines naturally calming ingredients with a flexible, easy-to-use format aimed at supporting emotional resilience in today’s high-stress landscape.

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.

TUESDAY INVESTOR DEADLINE: Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, July 18, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class...

PHREESIA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PHR

Attorney John Gomez Announces Whistleblower Retaliation Lawsuit on Behalf of Former Albert Einstein Academies Principal

BABCOCK & WILCOX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Babcock & Wilcox Enterprises, Inc. Investors to Secure Counsel Before Important June 15 Deadline in...

Scaling Self-Care Can Be a Game-Changer in Global Fight Against Non-Communicable Diseases

British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Doceree launches co-pay.com, an initiative to build the largest database of co-pay and affordability programs

Telix Reports $204M Revenue, Up 63% YOY

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Health In Tech Announces Second Quarter 2025 Financial Results

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

Natural Appetite Suppressant: Why More Are Choosing PhenQ Over Weight Loss Injections for Safer Weight Management Results in 2025

MY DR NOW Adds Seventh Clinic in Mesa with Same-Day Healthcare

The Wholesome Company Launches Rē•prev, a Calming Drink Mix for Anxiousness Support

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

TUESDAY INVESTOR DEADLINE: Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us